STTK logo

Shattuck Labs Inc. (STTK)

$4.66

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on STTK

Market cap

$474586292

EPS

-0.44

P/E ratio

--

Price to sales

599.17

Dividend yield

--

Beta

1.216316

Price on STTK

Previous close

$4.65

Today's open

$4.61

Day's range

$4.52 - $4.83

52 week range

$1.86 - $8.33

Profile about STTK

CEO

Taylor Schreiber

Employees

40

Headquarters

Austin, TX

Exchange

Nasdaq Global Select

Shares outstanding

101842552

Issue type

Common Stock

STTK industries and sectors

Healthcare

Biotechnology & Life Sciences

News on STTK

Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AUSTIN, Texas and DURHAM, N.C., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it has granted inducement equity awards on November 10, 2026 (the “Grant Date”) to two newly-hired non-executive employees.

news source

GlobeNewsWire • Nov 12, 2026

news preview

Shattuck Labs Reports Third Quarter 2026 Financial Results and Recent Business Highlights

– Initiated the RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in Crohn's disease; 12-week induction data expected in the first half of 2028 – – Announced RECEPTIVE-HS1 Phase 2 clinical trial of SL-325 in hidradenitis suppurativa; trial initiation expected in the fourth quarter of 2026 – – Presented preclinical data for SL-846 at UEG Week 2026, including data from a chronic toxicology study in non-human primates – AUSTIN, Texas and DURHAM, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2026 and provided recent business highlights.

news source

GlobeNewsWire • Nov 5, 2026

news preview

Shattuck Labs Announces Two Poster Presentations at UEG Week 2026

AUSTIN, Texas and DURHAM, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced two upcoming poster presentations at United European Gastroenterology (UEG) Week 2026, taking place October 17–20, 2026, in Barcelona, Spain.

news source

GlobeNewsWire • Oct 13, 2026

news preview

Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

–   RECEPTIVE-HS1 Phase 2 clinical trial in patients with moderate to severe hidradenitis suppurativa (HS) expected to initiate in 2026; data from the 16-week treatment period expected in the first half of 2028   – –   HS is the second Phase 2 indication for SL-325 and expands development beyond IBD   – –   Announces appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development; Dr. Ravichandran to lead the HS clinical development program   – –   Cash runway guidance remains unchanged, with existing cash expected to fund operations into 2029   –  AUSTIN, TX and DURHAM, NC, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced its plans to evaluate SL-325 in a Phase 2 clinical trial in patients with moderate to severe hidradenitis suppurativa (HS).

news source

GlobeNewsWire • Oct 1, 2026

news preview

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

AUSTIN, Texas and DURHAM, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences:

news source

GlobeNewsWire • Sep 2, 2026

news preview

Shattuck Labs: A Receptor-Side Bet On The TL1A Boom

Shattuck Labs pivots to immunology, focusing on DR3-targeted therapies for IBD, notably SL-325, after discontinuing its oncology program. SL-325's Phase 1 data show strong safety, low immunogenicity (3.7% ADA rate), and durable receptor occupancy, supporting quarterly dosing potential. STTK is fully funded through Phase 2b efficacy readout, with cash runway into 2029 despite significant dilution; valuation trades at a forward price-to-book discount.

news source

Seeking Alpha • Sep 1, 2026

news preview

What Shattuck Labs Stock Topped the Market on Monday

One of them initiated coverage. The company has a very promising lead drug candidate.

news source

The Motley Fool • Aug 24, 2026

news preview

Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy?

Does Shattuck Labs, Inc. (STTK) have what it takes to be a top stock pick for momentum investors? Let's find out.

news source

Zacks Investment Research • Aug 20, 2026

news preview

Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade

The consensus price target hints at an 85.3% upside potential for Shattuck Labs (STTK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

news source

Zacks Investment Research • Aug 13, 2026

news preview

Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday

He was encouraged by the progress of the company's SL-325. This, the biotech's lead drug candidate, is about to enter Phase 2 clinical testing.

news source

The Motley Fool • Jul 24, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Shattuck Labs Inc.

Open an M1 investment account to buy and sell Shattuck Labs Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in STTK on M1